ReportWire

Tag: Institutional Investor Holdings

  • Park Place Capital Corp Buys 4,520 Shares of Copart, Inc. (NASDAQ:CPRT)

    Park Place Capital Corp Buys 4,520 Shares of Copart, Inc. (NASDAQ:CPRT)

    [ad_1]

    Park Place Capital Corp grew its stake in shares of Copart, Inc. (NASDAQ:CPRT – Free Report) by 27.3% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 21,068 shares of the business services provider’s stock after buying an additional 4,520 shares during the period. Park Place Capital Corp’s holdings in Copart were worth $1,104,000 as of its most recent filing with the Securities and Exchange Commission.

    Several other institutional investors also recently modified their holdings of CPRT. Rise Advisors LLC bought a new stake in shares of Copart in the 1st quarter valued at $28,000. Pinnacle Bancorp Inc. lifted its holdings in Copart by 79.6% during the first quarter. Pinnacle Bancorp Inc. now owns 528 shares of the business services provider’s stock worth $31,000 after acquiring an additional 234 shares in the last quarter. Crewe Advisors LLC lifted its holdings in Copart by 98.6% during the second quarter. Crewe Advisors LLC now owns 564 shares of the business services provider’s stock worth $31,000 after acquiring an additional 280 shares in the last quarter. Meeder Asset Management Inc. lifted its holdings in Copart by 283.3% during the second quarter. Meeder Asset Management Inc. now owns 575 shares of the business services provider’s stock worth $31,000 after acquiring an additional 425 shares in the last quarter. Finally, Versant Capital Management Inc lifted its holdings in Copart by 477.7% during the second quarter. Versant Capital Management Inc now owns 595 shares of the business services provider’s stock worth $32,000 after acquiring an additional 492 shares in the last quarter. 85.78% of the stock is currently owned by institutional investors and hedge funds.

    Copart Price Performance

    NASDAQ CPRT traded up $0.75 during trading on Tuesday, reaching $53.51. 912,546 shares of the company’s stock were exchanged, compared to its average volume of 4,446,221. The business has a 50 day moving average price of $51.51 and a 200-day moving average price of $53.42. The stock has a market capitalization of $51.49 billion, a P/E ratio of 37.15 and a beta of 1.27. Copart, Inc. has a fifty-two week low of $42.41 and a fifty-two week high of $58.58.

    Copart (NASDAQ:CPRT – Get Free Report) last announced its quarterly earnings results on Wednesday, September 4th. The business services provider reported $0.33 earnings per share for the quarter, missing analysts’ consensus estimates of $0.36 by ($0.03). Copart had a return on equity of 19.55% and a net margin of 32.17%. The business had revenue of $1.07 billion for the quarter, compared to analyst estimates of $1.07 billion. During the same period last year, the firm earned $0.34 EPS. Copart’s quarterly revenue was up 7.2% compared to the same quarter last year. On average, analysts forecast that Copart, Inc. will post 1.54 earnings per share for the current year.

    Analyst Ratings Changes

    Separately, Robert W. Baird cut their price target on Copart from $58.00 to $56.00 and set an “outperform” rating on the stock in a report on Thursday, September 5th.

    Check Out Our Latest Stock Report on Copart

    About Copart

    (Free Report)

    Copart, Inc provides online auctions and vehicle remarketing services. It offers a range of services for processing and selling vehicles over the Internet through its Virtual Bidding Third Generation Internet auction-style sales technology on behalf of vehicle sellers, insurance companies, banks and finance companies, charities, and fleet operators and dealers, as well as individual owners.

    Further Reading

    Institutional Ownership by Quarter for Copart (NASDAQ:CPRT)

    Receive News & Ratings for Copart Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Copart and related companies with MarketBeat.com’s FREE daily email newsletter.

    [ad_2]

    ABMN Staff

    Source link

  • 105,433 Shares in TXO Partners, L.P. (NYSE:TXO) Bought by Sei Investments Co.

    105,433 Shares in TXO Partners, L.P. (NYSE:TXO) Bought by Sei Investments Co.

    [ad_1]

    Sei Investments Co. bought a new position in shares of TXO Partners, L.P. (NYSE:TXO – Free Report) in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 105,433 shares of the company’s stock, valued at approximately $2,126,000.

    Other institutional investors and hedge funds have also recently bought and sold shares of the company. Silverleafe Capital Partners LLC purchased a new stake in TXO Partners in the second quarter valued at $685,000. Hsbc Holdings PLC purchased a new stake in TXO Partners in the fourth quarter valued at $2,685,000. Raymond James & Associates lifted its position in TXO Partners by 43.4% in the second quarter. Raymond James & Associates now owns 234,488 shares of the company’s stock valued at $4,727,000 after acquiring an additional 70,918 shares during the last quarter. Pin Oak Investment Advisors Inc. purchased a new stake in TXO Partners in the fourth quarter valued at $4,346,000. Finally, Energy Income Partners LLC lifted its position in TXO Partners by 37.7% in the first quarter. Energy Income Partners LLC now owns 493,438 shares of the company’s stock valued at $8,857,000 after acquiring an additional 135,029 shares during the last quarter. 27.44% of the stock is owned by hedge funds and other institutional investors.

    TXO Partners Price Performance

    Shares of TXO opened at $19.07 on Friday. TXO Partners, L.P. has a 1-year low of $17.20 and a 1-year high of $23.56. The stock has a market cap of $732.48 million, a PE ratio of -3.26 and a beta of 0.05. The company has a debt-to-equity ratio of 0.01, a current ratio of 3.27 and a quick ratio of 3.26. The firm has a fifty day moving average price of $18.85 and a 200 day moving average price of $19.82.

    TXO Partners (NYSE:TXO – Get Free Report) last announced its quarterly earnings results on Tuesday, August 6th. The company reported $0.09 earnings per share for the quarter, missing analysts’ consensus estimates of $0.19 by ($0.10). TXO Partners had a negative net margin of 60.08% and a positive return on equity of 9.33%. The company had revenue of $57.31 million during the quarter, compared to analysts’ expectations of $63.77 million. As a group, sell-side analysts anticipate that TXO Partners, L.P. will post 0.98 EPS for the current year.

    TXO Partners Cuts Dividend

    The firm also recently announced a quarterly dividend, which was paid on Tuesday, August 27th. Stockholders of record on Tuesday, August 20th were issued a $0.57 dividend. The ex-dividend date of this dividend was Tuesday, August 20th. This represents a $2.28 dividend on an annualized basis and a dividend yield of 11.96%. TXO Partners’s payout ratio is -38.97%.

    TXO Partners Company Profile

    (Free Report)

    TXO Partners, L.P., an oil and natural gas company, focuses on the acquisition, development, optimization, and exploitation of conventional oil, natural gas, and natural gas liquid reserves in North America. Its acreage positions are concentrated in the Permian Basin of West Texas and New Mexico and the San Juan Basin of New Mexico and Colorado.

    Read More

    Want to see what other hedge funds are holding TXO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for TXO Partners, L.P. (NYSE:TXO – Free Report).

    Institutional Ownership by Quarter for TXO Partners (NYSE:TXO)

    Receive News & Ratings for TXO Partners Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for TXO Partners and related companies with MarketBeat.com’s FREE daily email newsletter.

    [ad_2]

    ABMN Staff

    Source link

  • Second Line Capital LLC Acquires 3,016 Shares of Verizon Communications Inc. (NYSE:VZ)

    Second Line Capital LLC Acquires 3,016 Shares of Verizon Communications Inc. (NYSE:VZ)

    [ad_1]

    Second Line Capital LLC grew its holdings in Verizon Communications Inc. (NYSE:VZ – Free Report) by 44.4% in the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 9,811 shares of the cell phone carrier’s stock after acquiring an additional 3,016 shares during the period. Second Line Capital LLC’s holdings in Verizon Communications were worth $405,000 as of its most recent SEC filing.

    Several other hedge funds also recently modified their holdings of the business. Alliance Wealth Advisors LLC grew its holdings in shares of Verizon Communications by 1.4% during the 2nd quarter. Alliance Wealth Advisors LLC now owns 17,760 shares of the cell phone carrier’s stock worth $732,000 after purchasing an additional 241 shares in the last quarter. Semmax Financial Advisors Inc. lifted its position in Verizon Communications by 0.4% in the second quarter. Semmax Financial Advisors Inc. now owns 54,926 shares of the cell phone carrier’s stock worth $2,240,000 after purchasing an additional 246 shares during the period. Sawgrass Asset Management LLC boosted its stake in Verizon Communications by 1.2% during the second quarter. Sawgrass Asset Management LLC now owns 21,568 shares of the cell phone carrier’s stock worth $889,000 after buying an additional 250 shares in the last quarter. Fermata Advisors LLC increased its holdings in Verizon Communications by 5.0% in the 2nd quarter. Fermata Advisors LLC now owns 5,383 shares of the cell phone carrier’s stock valued at $222,000 after buying an additional 254 shares during the period. Finally, BKM Wealth Management LLC raised its stake in shares of Verizon Communications by 7.4% in the 1st quarter. BKM Wealth Management LLC now owns 3,715 shares of the cell phone carrier’s stock valued at $156,000 after buying an additional 257 shares in the last quarter. Institutional investors and hedge funds own 62.06% of the company’s stock.

    Verizon Communications Stock Performance

    Shares of Verizon Communications stock opened at $44.89 on Monday. The company has a debt-to-equity ratio of 1.29, a current ratio of 0.63 and a quick ratio of 0.60. The firm has a 50 day simple moving average of $41.76 and a 200 day simple moving average of $40.95. Verizon Communications Inc. has a fifty-two week low of $30.14 and a fifty-two week high of $45.05. The firm has a market cap of $188.95 billion, a P/E ratio of 16.75, a P/E/G ratio of 4.03 and a beta of 0.42.

    Verizon Communications (NYSE:VZ – Get Free Report) last released its earnings results on Monday, July 22nd. The cell phone carrier reported $1.15 earnings per share for the quarter, hitting analysts’ consensus estimates of $1.15. The company had revenue of $32.80 billion during the quarter, compared to the consensus estimate of $33.05 billion. Verizon Communications had a return on equity of 20.10% and a net margin of 8.38%. The firm’s quarterly revenue was up .6% on a year-over-year basis. During the same quarter in the previous year, the company posted $1.21 earnings per share. Sell-side analysts predict that Verizon Communications Inc. will post 4.58 earnings per share for the current fiscal year.

    Verizon Communications Increases Dividend

    The business also recently disclosed a quarterly dividend, which will be paid on Friday, November 1st. Investors of record on Thursday, October 10th will be paid a dividend of $0.678 per share. The ex-dividend date is Thursday, October 10th. This is a boost from Verizon Communications’s previous quarterly dividend of $0.67. This represents a $2.71 dividend on an annualized basis and a dividend yield of 6.04%. Verizon Communications’s payout ratio is 101.12%.

    Wall Street Analyst Weigh In

    A number of research firms recently weighed in on VZ. TD Cowen upped their target price on shares of Verizon Communications from $48.00 to $51.00 and gave the company a “buy” rating in a research note on Tuesday, July 23rd. Bank of America upped their price objective on Verizon Communications from $41.00 to $45.00 and gave the company a “neutral” rating in a research note on Thursday. Citigroup raised their target price on Verizon Communications from $47.00 to $49.00 and gave the stock a “buy” rating in a research report on Wednesday, September 25th. The Goldman Sachs Group initiated coverage on Verizon Communications in a research report on Monday, July 1st. They issued a “buy” rating and a $50.00 price target on the stock. Finally, Raymond James lifted their price objective on Verizon Communications from $44.00 to $48.00 and gave the company an “outperform” rating in a report on Tuesday, September 24th. Eight investment analysts have rated the stock with a hold rating and ten have given a buy rating to the company. According to data from MarketBeat, Verizon Communications presently has an average rating of “Moderate Buy” and an average price target of $46.09.

    Read Our Latest Research Report on VZ

    Verizon Communications Company Profile

    (Free Report)

    Verizon Communications Inc, through its subsidiaries, engages in the provision of communications, technology, information, and entertainment products and services to consumers, businesses, and governmental entities worldwide. It operates in two segments, Verizon Consumer Group (Consumer) and Verizon Business Group (Business).

    Recommended Stories

    Institutional Ownership by Quarter for Verizon Communications (NYSE:VZ)

    Receive News & Ratings for Verizon Communications Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Verizon Communications and related companies with MarketBeat.com’s FREE daily email newsletter.

    [ad_2]

    ABMN Staff

    Source link

  • Fred Alger Management LLC Has $16.24 Million Stock Holdings in Nevro Corp. (NYSE:NVRO)

    Fred Alger Management LLC Has $16.24 Million Stock Holdings in Nevro Corp. (NYSE:NVRO)

    [ad_1]

    Fred Alger Management LLC lowered its position in shares of Nevro Corp. (NYSE:NVRO – Free Report) by 7.5% in the second quarter, according to its most recent disclosure with the SEC. The institutional investor owned 1,928,144 shares of the medical equipment provider’s stock after selling 155,543 shares during the quarter. Fred Alger Management LLC owned about 5.25% of Nevro worth $16,235,000 as of its most recent SEC filing.

    A number of other hedge funds and other institutional investors also recently modified their holdings of NVRO. Charles Schwab Investment Management Inc. raised its position in shares of Nevro by 1.4% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 280,528 shares of the medical equipment provider’s stock valued at $6,037,000 after buying an additional 3,860 shares in the last quarter. Norges Bank bought a new stake in shares of Nevro during the 4th quarter valued at $8,498,000. Assetmark Inc. grew its holdings in shares of Nevro by 30.4% during the 4th quarter. Assetmark Inc. now owns 3,131 shares of the medical equipment provider’s stock worth $67,000 after purchasing an additional 730 shares in the last quarter. Goldman Sachs Group Inc. increased its position in shares of Nevro by 69.9% in the fourth quarter. Goldman Sachs Group Inc. now owns 1,048,026 shares of the medical equipment provider’s stock worth $22,554,000 after purchasing an additional 431,136 shares during the period. Finally, Nomura Holdings Inc. raised its stake in Nevro by 28.1% in the fourth quarter. Nomura Holdings Inc. now owns 59,250 shares of the medical equipment provider’s stock valued at $1,275,000 after purchasing an additional 13,000 shares in the last quarter. Institutional investors and hedge funds own 95.52% of the company’s stock.

    Nevro Price Performance

    Nevro stock opened at $5.40 on Thursday. The company has a market capitalization of $201.31 million, a PE ratio of -2.36 and a beta of 0.94. The company has a current ratio of 4.77, a quick ratio of 3.53 and a debt-to-equity ratio of 0.66. The stock has a 50-day moving average price of $6.64 and a two-hundred day moving average price of $9.43. Nevro Corp. has a 12 month low of $4.38 and a 12 month high of $22.64.

    Nevro (NYSE:NVRO – Get Free Report) last issued its quarterly earnings data on Tuesday, August 6th. The medical equipment provider reported ($0.53) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.63) by $0.10. Nevro had a negative net margin of 18.17% and a negative return on equity of 24.89%. The business had revenue of $104.16 million during the quarter, compared to analyst estimates of $107.11 million. During the same quarter last year, the business earned ($0.69) EPS. The firm’s quarterly revenue was down 4.3% on a year-over-year basis. Analysts expect that Nevro Corp. will post -2.6 EPS for the current year.

    Wall Street Analysts Forecast Growth

    A number of brokerages have issued reports on NVRO. Robert W. Baird reduced their price objective on shares of Nevro from $11.00 to $8.00 and set a “neutral” rating on the stock in a research note on Wednesday, August 7th. Wells Fargo & Company lowered shares of Nevro from an “equal weight” rating to an “underweight” rating and reduced their price target for the stock from $13.00 to $5.50 in a research report on Wednesday, August 7th. JPMorgan Chase & Co. downgraded shares of Nevro from a “neutral” rating to an “underweight” rating in a research report on Wednesday, August 7th. Piper Sandler reduced their target price on Nevro from $12.00 to $7.00 and set an “underweight” rating on the stock in a report on Wednesday, August 7th. Finally, Truist Financial lowered their price target on Nevro from $10.00 to $5.50 and set a “hold” rating for the company in a report on Thursday, August 8th. Four analysts have rated the stock with a sell rating and eleven have issued a hold rating to the company. According to MarketBeat, the company has an average rating of “Hold” and an average target price of $10.63.

    Check Out Our Latest Analysis on Nevro

    Nevro Company Profile

    (Free Report)

    Nevro Corp., a medical device company, engages in the provision of products for patients suffering from chronic pain in the United States and internationally. The company provides HFX spinal cord stimulation (SCS) platform, which includes the Senza SCS implantable pulse generator (IPG) system, an evidence-based neuromodulation system for the treatment of chronic back and leg pain through paresthesia-free 10 kHz therapy, as well as offers Senza II and Senza Omnia SCS IPG systems.

    Read More

    Institutional Ownership by Quarter for Nevro (NYSE:NVRO)

    Receive News & Ratings for Nevro Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Nevro and related companies with MarketBeat.com’s FREE daily email newsletter.

    [ad_2]

    ABMN Staff

    Source link

  • Sei Investments Co. Increases Holdings in U.S. Bancorp (NYSE:USB)

    Sei Investments Co. Increases Holdings in U.S. Bancorp (NYSE:USB)

    [ad_1]

    Sei Investments Co. grew its holdings in U.S. Bancorp (NYSE:USB – Free Report) by 5.1% during the second quarter, HoldingsChannel reports. The fund owned 1,852,257 shares of the financial services provider’s stock after purchasing an additional 90,691 shares during the period. Sei Investments Co.’s holdings in U.S. Bancorp were worth $73,535,000 as of its most recent SEC filing.

    Several other hedge funds and other institutional investors have also made changes to their positions in USB. Redwood Wealth Management Group LLC purchased a new position in U.S. Bancorp in the second quarter valued at approximately $25,000. Financial Synergies Wealth Advisors Inc. acquired a new position in shares of U.S. Bancorp in the 1st quarter valued at $30,000. LRI Investments LLC purchased a new position in shares of U.S. Bancorp in the 1st quarter valued at $31,000. Eagle Bay Advisors LLC raised its stake in U.S. Bancorp by 93.2% during the 1st quarter. Eagle Bay Advisors LLC now owns 686 shares of the financial services provider’s stock worth $31,000 after acquiring an additional 331 shares in the last quarter. Finally, 1620 Investment Advisors Inc. purchased a new stake in U.S. Bancorp in the second quarter valued at $30,000. Institutional investors and hedge funds own 77.60% of the company’s stock.

    U.S. Bancorp Trading Down 1.0 %

    NYSE:USB opened at $46.01 on Friday. U.S. Bancorp has a 1 year low of $30.47 and a 1 year high of $47.31. The company has a debt-to-equity ratio of 1.05, a quick ratio of 0.80 and a current ratio of 0.81. The stock has a fifty day moving average price of $44.39 and a two-hundred day moving average price of $42.31. The stock has a market capitalization of $71.80 billion, a price-to-earnings ratio of 15.24, a PEG ratio of 4.36 and a beta of 1.04.

    U.S. Bancorp (NYSE:USB – Get Free Report) last released its quarterly earnings data on Wednesday, July 17th. The financial services provider reported $0.98 EPS for the quarter, topping analysts’ consensus estimates of $0.94 by $0.04. U.S. Bancorp had a net margin of 12.55% and a return on equity of 13.34%. The firm had revenue of $6.87 billion for the quarter, compared to the consensus estimate of $6.81 billion. During the same quarter in the previous year, the firm earned $1.12 earnings per share. The firm’s revenue was down 4.3% on a year-over-year basis. As a group, sell-side analysts anticipate that U.S. Bancorp will post 3.87 earnings per share for the current fiscal year.

    U.S. Bancorp announced that its board has approved a stock repurchase plan on Thursday, September 12th that allows the company to repurchase $5.00 billion in outstanding shares. This repurchase authorization allows the financial services provider to purchase up to 7% of its stock through open market purchases. Stock repurchase plans are usually a sign that the company’s board of directors believes its shares are undervalued.

    U.S. Bancorp Increases Dividend

    The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, October 15th. Investors of record on Monday, September 30th will be paid a $0.50 dividend. This is an increase from U.S. Bancorp’s previous quarterly dividend of $0.49. This represents a $2.00 annualized dividend and a yield of 4.35%. The ex-dividend date of this dividend is Monday, September 30th. U.S. Bancorp’s dividend payout ratio (DPR) is presently 66.23%.

    Insider Buying and Selling

    In other news, Director Aleem Gillani purchased 10,000 shares of the company’s stock in a transaction dated Thursday, July 18th. The stock was acquired at an average price of $44.99 per share, for a total transaction of $449,900.00. Following the completion of the transaction, the director now directly owns 10,000 shares in the company, valued at approximately $449,900. The acquisition was disclosed in a document filed with the SEC, which is accessible through this link. 0.23% of the stock is currently owned by insiders.

    Analyst Ratings Changes

    USB has been the topic of a number of research analyst reports. UBS Group lifted their target price on U.S. Bancorp from $43.00 to $46.00 and gave the stock a “neutral” rating in a research report on Thursday, July 18th. Citigroup lifted their price target on U.S. Bancorp from $45.00 to $49.00 and gave the stock a “neutral” rating in a research report on Thursday, July 18th. JPMorgan Chase & Co. downgraded U.S. Bancorp from an “overweight” rating to a “neutral” rating and set a $43.50 price objective for the company. in a report on Thursday, June 27th. StockNews.com raised shares of U.S. Bancorp from a “sell” rating to a “hold” rating in a report on Wednesday, July 17th. Finally, Wells Fargo & Company increased their price target on shares of U.S. Bancorp from $48.00 to $52.00 and gave the stock an “overweight” rating in a research note on Thursday, July 18th. Thirteen investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Hold” and an average target price of $48.18.

    Get Our Latest Analysis on U.S. Bancorp

    About U.S. Bancorp

    (Free Report)

    U.S. Bancorp, a financial services holding company, provides various financial services to individuals, businesses, institutional organizations, governmental entities, and other financial institutions in the United States. It operates through Wealth, Corporate, Commercial and Institutional Banking; Consumer and Business Banking; Payment Services; and Treasury and Corporate Support segments.

    Recommended Stories

    Want to see what other hedge funds are holding USB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for U.S. Bancorp (NYSE:USB – Free Report).

    Institutional Ownership by Quarter for U.S. Bancorp (NYSE:USB)

    Receive News & Ratings for U.S. Bancorp Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for U.S. Bancorp and related companies with MarketBeat.com’s FREE daily email newsletter.

    [ad_2]

    ABMN Staff

    Source link

  • Blair William & Co. IL Has $8.20 Million Stock Holdings in Northrop Grumman Co. (NYSE:NOC)

    Blair William & Co. IL Has $8.20 Million Stock Holdings in Northrop Grumman Co. (NYSE:NOC)

    [ad_1]

    Blair William & Co. IL lessened its position in shares of Northrop Grumman Co. (NYSE:NOC – Free Report) by 16.2% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 18,813 shares of the aerospace company’s stock after selling 3,635 shares during the period. Blair William & Co. IL’s holdings in Northrop Grumman were worth $8,202,000 at the end of the most recent reporting period.

    Other hedge funds and other institutional investors have also bought and sold shares of the company. Capital International Investors increased its position in shares of Northrop Grumman by 5.6% in the first quarter. Capital International Investors now owns 11,747,646 shares of the aerospace company’s stock valued at $5,623,128,000 after acquiring an additional 621,636 shares during the last quarter. JPMorgan Chase & Co. lifted its holdings in Northrop Grumman by 4.8% during the 1st quarter. JPMorgan Chase & Co. now owns 4,634,043 shares of the aerospace company’s stock worth $2,218,132,000 after purchasing an additional 211,459 shares during the last quarter. Capital World Investors lifted its holdings in shares of Northrop Grumman by 0.6% during the first quarter. Capital World Investors now owns 3,688,511 shares of the aerospace company’s stock worth $1,765,543,000 after buying an additional 23,398 shares in the last quarter. Sanders Capital LLC boosted its holdings in Northrop Grumman by 3.7% in the 4th quarter. Sanders Capital LLC now owns 2,271,466 shares of the aerospace company’s stock valued at $1,063,364,000 after purchasing an additional 80,887 shares during the period. Finally, Northern Trust Corp boosted its stake in shares of Northrop Grumman by 1.3% in the fourth quarter. Northern Trust Corp now owns 1,260,599 shares of the aerospace company’s stock valued at $590,137,000 after buying an additional 16,275 shares during the period. Institutional investors and hedge funds own 83.40% of the company’s stock.

    Analyst Ratings Changes

    NOC has been the subject of several recent analyst reports. Sanford C. Bernstein cut shares of Northrop Grumman from an “outperform” rating to a “market perform” rating and set a $477.00 price objective for the company. in a research report on Friday, June 21st. Morgan Stanley boosted their price objective on Northrop Grumman from $579.00 to $592.00 and gave the stock an “overweight” rating in a research report on Friday, August 9th. Barclays raised their price target on shares of Northrop Grumman from $470.00 to $500.00 and gave the company an “equal weight” rating in a research note on Tuesday, July 30th. Deutsche Bank Aktiengesellschaft raised Northrop Grumman from a “hold” rating to a “buy” rating and lifted their price objective for the stock from $474.00 to $575.00 in a research note on Monday, July 29th. Finally, Alembic Global Advisors cut shares of Northrop Grumman from an “overweight” rating to a “neutral” rating and set a $560.00 price target on the stock. in a research report on Tuesday, August 27th. One analyst has rated the stock with a sell rating, nine have issued a hold rating and six have assigned a buy rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Hold” and an average target price of $523.20.

    View Our Latest Report on NOC

    Insider Activity

    In other Northrop Grumman news, VP Thomas H. Jones sold 1,390 shares of the firm’s stock in a transaction on Friday, August 2nd. The stock was sold at an average price of $500.00, for a total value of $695,000.00. Following the completion of the sale, the vice president now directly owns 4,634 shares of the company’s stock, valued at $2,317,000. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In related news, VP Thomas H. Jones sold 1,390 shares of the business’s stock in a transaction dated Friday, August 2nd. The stock was sold at an average price of $500.00, for a total value of $695,000.00. Following the sale, the vice president now directly owns 4,634 shares in the company, valued at approximately $2,317,000. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, VP Thomas H. Jones sold 1,389 shares of the stock in a transaction dated Friday, July 26th. The stock was sold at an average price of $477.56, for a total transaction of $663,330.84. Following the transaction, the vice president now owns 6,755 shares of the company’s stock, valued at approximately $3,225,917.80. The disclosure for this sale can be found here. Insiders sold 2,846 shares of company stock valued at $1,393,028 in the last three months. Company insiders own 0.22% of the company’s stock.

    Northrop Grumman Price Performance

    Shares of NYSE NOC opened at $525.13 on Friday. The stock has a market cap of $77.71 billion, a price-to-earnings ratio of 36.72, a PEG ratio of 2.36 and a beta of 0.34. Northrop Grumman Co. has a fifty-two week low of $414.56 and a fifty-two week high of $528.76. The firm’s 50-day simple moving average is $496.06 and its 200 day simple moving average is $469.70. The company has a debt-to-equity ratio of 1.03, a quick ratio of 0.99 and a current ratio of 1.11.

    Northrop Grumman (NYSE:NOC – Get Free Report) last posted its earnings results on Thursday, July 25th. The aerospace company reported $6.36 earnings per share (EPS) for the quarter, topping the consensus estimate of $5.93 by $0.43. Northrop Grumman had a net margin of 5.61% and a return on equity of 25.44%. The firm had revenue of $10.22 billion during the quarter, compared to analyst estimates of $10.02 billion. During the same quarter in the prior year, the business posted $5.34 EPS. The business’s revenue was up 6.7% compared to the same quarter last year. As a group, research analysts anticipate that Northrop Grumman Co. will post 25.14 earnings per share for the current fiscal year.

    Northrop Grumman Announces Dividend

    The business also recently declared a quarterly dividend, which was paid on Wednesday, September 18th. Investors of record on Tuesday, September 3rd were given a dividend of $2.06 per share. The ex-dividend date of this dividend was Tuesday, September 3rd. This represents a $8.24 annualized dividend and a yield of 1.57%. Northrop Grumman’s payout ratio is currently 57.62%.

    Northrop Grumman Profile

    (Free Report)

    Northrop Grumman Corporation operates as an aerospace and defense technology company in the United States, Asia/Pacific, Europe, and internationally. The company’s Aeronautics Systems segment designs, develops, manufactures, integrates, and sustains aircraft systems. This segment also offers unmanned autonomous aircraft systems, including high-altitude long-endurance strategic ISR systems and vertical take-off and landing tactical ISR systems; and strategic long-range strike aircraft, tactical fighter and air dominance aircraft, and airborne battle management and command and control systems.

    See Also

    Want to see what other hedge funds are holding NOC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Northrop Grumman Co. (NYSE:NOC – Free Report).

    Institutional Ownership by Quarter for Northrop Grumman (NYSE:NOC)

    Receive News & Ratings for Northrop Grumman Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Northrop Grumman and related companies with MarketBeat.com’s FREE daily email newsletter.

    [ad_2]

    ABMN Staff

    Source link

  • State of New Jersey Common Pension Fund D Takes $2.21 Million Position in ADMA Biologics, Inc. (NASDAQ:ADMA)

    State of New Jersey Common Pension Fund D Takes $2.21 Million Position in ADMA Biologics, Inc. (NASDAQ:ADMA)

    [ad_1]

    State of New Jersey Common Pension Fund D acquired a new position in ADMA Biologics, Inc. (NASDAQ:ADMA – Free Report) during the second quarter, according to the company in its most recent disclosure with the SEC. The firm acquired 197,856 shares of the biotechnology company’s stock, valued at approximately $2,212,000. State of New Jersey Common Pension Fund D owned 0.09% of ADMA Biologics as of its most recent SEC filing.

    Other hedge funds have also recently bought and sold shares of the company. Quest Partners LLC bought a new position in ADMA Biologics in the 2nd quarter worth about $29,000. EntryPoint Capital LLC acquired a new stake in ADMA Biologics in the 1st quarter valued at approximately $31,000. Simplicity Wealth LLC bought a new stake in ADMA Biologics during the 1st quarter valued at $68,000. Oxford Asset Management LLP acquired a new position in ADMA Biologics during the 4th quarter worth $83,000. Finally, CWM LLC grew its stake in shares of ADMA Biologics by 114.2% in the second quarter. CWM LLC now owns 8,192 shares of the biotechnology company’s stock worth $92,000 after purchasing an additional 4,367 shares in the last quarter. 75.68% of the stock is currently owned by institutional investors.

    Analyst Ratings Changes

    ADMA has been the topic of a number of recent analyst reports. Cantor Fitzgerald lifted their price objective on shares of ADMA Biologics from $15.00 to $20.00 and gave the company an “overweight” rating in a research note on Friday, August 9th. HC Wainwright upped their price target on shares of ADMA Biologics from $10.00 to $18.00 and gave the stock a “buy” rating in a research note on Monday, August 12th. Finally, Mizuho raised their price objective on shares of ADMA Biologics from $12.00 to $14.00 and gave the company a “buy” rating in a research note on Thursday, June 20th. One research analyst has rated the stock with a hold rating, three have issued a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the stock has an average rating of “Buy” and a consensus price target of $15.50.

    View Our Latest Report on ADMA Biologics

    Insider Buying and Selling

    In related news, COO Kaitlin M. Kestenberg-Messina sold 24,150 shares of the stock in a transaction on Friday, August 30th. The stock was sold at an average price of $16.90, for a total value of $408,135.00. Following the completion of the transaction, the chief operating officer now owns 449,088 shares in the company, valued at approximately $7,589,587.20. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. In other ADMA Biologics news, COO Kaitlin M. Kestenberg-Messina sold 24,150 shares of ADMA Biologics stock in a transaction that occurred on Friday, August 30th. The shares were sold at an average price of $16.90, for a total transaction of $408,135.00. Following the transaction, the chief operating officer now directly owns 449,088 shares in the company, valued at approximately $7,589,587.20. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Young Kwon sold 60,000 shares of the stock in a transaction on Friday, August 23rd. The shares were sold at an average price of $18.26, for a total value of $1,095,600.00. Following the completion of the sale, the director now owns 241,441 shares of the company’s stock, valued at approximately $4,408,712.66. The disclosure for this sale can be found here. Insiders have sold 466,900 shares of company stock worth $8,224,121 in the last three months. 3.70% of the stock is currently owned by insiders.

    ADMA Biologics Price Performance

    Shares of NASDAQ ADMA opened at $19.74 on Friday. ADMA Biologics, Inc. has a twelve month low of $3.06 and a twelve month high of $19.92. The company has a current ratio of 6.87, a quick ratio of 2.80 and a debt-to-equity ratio of 0.74. The firm has a 50-day moving average of $15.63 and a two-hundred day moving average of $10.83. The company has a market capitalization of $4.58 billion, a price-to-earnings ratio of -987.00 and a beta of 0.61.

    ADMA Biologics (NASDAQ:ADMA – Get Free Report) last issued its earnings results on Thursday, August 8th. The biotechnology company reported $0.13 earnings per share for the quarter, topping analysts’ consensus estimates of $0.08 by $0.05. The firm had revenue of $107.20 million during the quarter, compared to analysts’ expectations of $86.44 million. ADMA Biologics had a net margin of 10.53% and a return on equity of 38.79%. The firm’s revenue for the quarter was up 78.4% compared to the same quarter last year. During the same period last year, the firm posted ($0.02) earnings per share. As a group, analysts expect that ADMA Biologics, Inc. will post 0.49 earnings per share for the current fiscal year.

    ADMA Biologics Company Profile

    (Free Report)

    ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.

    Recommended Stories

    Want to see what other hedge funds are holding ADMA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for ADMA Biologics, Inc. (NASDAQ:ADMA – Free Report).

    Institutional Ownership by Quarter for ADMA Biologics (NASDAQ:ADMA)

    Receive News & Ratings for ADMA Biologics Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for ADMA Biologics and related companies with MarketBeat.com’s FREE daily email newsletter.

    [ad_2]

    ABMN Staff

    Source link

  • E Fund Management Co. Ltd. Boosts Stake in Starbucks Co. (NASDAQ:SBUX)

    E Fund Management Co. Ltd. Boosts Stake in Starbucks Co. (NASDAQ:SBUX)

    [ad_1]

    E Fund Management Co. Ltd. lifted its stake in Starbucks Co. (NASDAQ:SBUX – Free Report) by 1.8% in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 11,347 shares of the coffee company’s stock after purchasing an additional 204 shares during the period. E Fund Management Co. Ltd.’s holdings in Starbucks were worth $883,000 at the end of the most recent reporting period.

    Several other hedge funds and other institutional investors have also recently modified their holdings of SBUX. Gryphon Financial Partners LLC increased its stake in shares of Starbucks by 96.3% in the 4th quarter. Gryphon Financial Partners LLC now owns 5,213 shares of the coffee company’s stock worth $508,000 after purchasing an additional 2,558 shares in the last quarter. TrinityPoint Wealth LLC purchased a new stake in shares of Starbucks in the 4th quarter worth $230,000. Hillsdale Investment Management Inc. increased its stake in shares of Starbucks by 5.8% in the 4th quarter. Hillsdale Investment Management Inc. now owns 3,269 shares of the coffee company’s stock worth $314,000 after purchasing an additional 180 shares in the last quarter. Assetmark Inc. increased its stake in shares of Starbucks by 14.5% in the 4th quarter. Assetmark Inc. now owns 95,372 shares of the coffee company’s stock worth $9,157,000 after purchasing an additional 12,089 shares in the last quarter. Finally, EverSource Wealth Advisors LLC increased its stake in Starbucks by 2.6% in the 4th quarter. EverSource Wealth Advisors LLC now owns 12,697 shares of the coffee company’s stock worth $1,219,000 after buying an additional 324 shares in the last quarter. 72.29% of the stock is currently owned by hedge funds and other institutional investors.

    Starbucks Trading Down 0.3 %

    Shares of NASDAQ:SBUX opened at $96.12 on Thursday. Starbucks Co. has a 12 month low of $71.55 and a 12 month high of $107.66. The company has a 50-day moving average price of $85.77 and a 200 day moving average price of $83.98. The company has a market cap of $108.92 billion, a price-to-earnings ratio of 26.48, a PEG ratio of 2.38 and a beta of 0.96.

    Starbucks (NASDAQ:SBUX – Get Free Report) last announced its earnings results on Tuesday, July 30th. The coffee company reported $0.93 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.93. Starbucks had a negative return on equity of 49.38% and a net margin of 11.16%. The business had revenue of $9.11 billion during the quarter, compared to analyst estimates of $9.25 billion. During the same quarter in the previous year, the business earned $1.00 earnings per share. The company’s revenue for the quarter was down .6% compared to the same quarter last year. As a group, equities analysts forecast that Starbucks Co. will post 3.56 EPS for the current year.

    Insider Buying and Selling at Starbucks

    In other Starbucks news, CEO Rachel Ruggeri sold 3,290 shares of the business’s stock in a transaction that occurred on Tuesday, August 13th. The stock was sold at an average price of $91.16, for a total transaction of $299,916.40. Following the completion of the transaction, the chief executive officer now owns 62,502 shares in the company, valued at $5,697,682.32. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In other Starbucks news, CEO Rachel Ruggeri sold 3,290 shares of the business’s stock in a transaction that occurred on Tuesday, August 13th. The stock was sold at an average price of $91.16, for a total transaction of $299,916.40. Following the completion of the transaction, the chief executive officer now owns 62,502 shares in the company, valued at $5,697,682.32. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Jorgen Vig Knudstorp purchased 380 shares of the firm’s stock in a transaction dated Friday, September 6th. The shares were bought at an average cost of $91.50 per share, with a total value of $34,770.00. Following the purchase, the director now directly owns 36,242 shares of the company’s stock, valued at approximately $3,316,143. The disclosure for this purchase can be found here. Company insiders own 1.98% of the company’s stock.

    Wall Street Analyst Weigh In

    A number of brokerages have issued reports on SBUX. DZ Bank lowered Starbucks from a “hold” rating to a “sell” rating and set a $85.00 price target for the company. in a research note on Wednesday, August 21st. The Goldman Sachs Group began coverage on Starbucks in a research note on Thursday, June 13th. They issued a “buy” rating and a $100.00 price target for the company. Robert W. Baird upgraded Starbucks from a “neutral” rating to an “outperform” rating and increased their price target for the stock from $81.00 to $110.00 in a research note on Tuesday, August 13th. Evercore ISI upgraded Starbucks from an “in-line” rating to an “outperform” rating and increased their price target for the stock from $80.00 to $120.00 in a research note on Wednesday, August 14th. Finally, Deutsche Bank Aktiengesellschaft upgraded Starbucks from a “hold” rating to a “buy” rating and increased their price target for the stock from $85.00 to $118.00 in a research note on Wednesday, August 14th. One analyst has rated the stock with a sell rating, eleven have given a hold rating, fifteen have assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, Starbucks has an average rating of “Moderate Buy” and a consensus price target of $100.08.

    Get Our Latest Stock Report on SBUX

    Starbucks Profile

    (Free Report)

    Starbucks Corporation, together with its subsidiaries, operates as a roaster, marketer, and retailer of coffee worldwide. The company operates through three segments: North America, International, and Channel Development. Its stores offer coffee and tea beverages, roasted whole beans and ground coffees, single serve products, and ready-to-drink beverages; and various food products, such as pastries, breakfast sandwiches, and lunch items.

    Read More

    Institutional Ownership by Quarter for Starbucks (NASDAQ:SBUX)

    Receive News & Ratings for Starbucks Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Starbucks and related companies with MarketBeat.com’s FREE daily email newsletter.

    [ad_2]

    ABMN Staff

    Source link

  • Headlands Technologies LLC Increases Position in SPDR S&P Insurance ETF (NYSEARCA:KIE)

    Headlands Technologies LLC Increases Position in SPDR S&P Insurance ETF (NYSEARCA:KIE)

    [ad_1]

    Headlands Technologies LLC grew its position in shares of SPDR S&P Insurance ETF (NYSEARCA:KIE – Free Report) by 598.5% during the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,355 shares of the exchange traded fund’s stock after purchasing an additional 1,161 shares during the period. Headlands Technologies LLC’s holdings in SPDR S&P Insurance ETF were worth $68,000 as of its most recent SEC filing.

    A number of other large investors also recently added to or reduced their stakes in the company. UBS Group AG lifted its stake in SPDR S&P Insurance ETF by 440.5% during the fourth quarter. UBS Group AG now owns 446,056 shares of the exchange traded fund’s stock worth $20,171,000 after purchasing an additional 363,536 shares in the last quarter. Raymond James & Associates lifted its stake in SPDR S&P Insurance ETF by 261.0% during the second quarter. Raymond James & Associates now owns 169,728 shares of the exchange traded fund’s stock worth $8,458,000 after purchasing an additional 122,709 shares in the last quarter. Kingsview Wealth Management LLC lifted its stake in SPDR S&P Insurance ETF by 345.7% during the first quarter. Kingsview Wealth Management LLC now owns 130,814 shares of the exchange traded fund’s stock worth $6,812,000 after purchasing an additional 101,462 shares in the last quarter. Zimmermann Investment Management & Planning LLC lifted its stake in SPDR S&P Insurance ETF by 18.9% during the second quarter. Zimmermann Investment Management & Planning LLC now owns 95,178 shares of the exchange traded fund’s stock worth $4,743,000 after purchasing an additional 15,137 shares in the last quarter. Finally, Cambridge Investment Research Advisors Inc. lifted its stake in SPDR S&P Insurance ETF by 1,142.4% during the first quarter. Cambridge Investment Research Advisors Inc. now owns 83,702 shares of the exchange traded fund’s stock worth $4,358,000 after purchasing an additional 76,965 shares in the last quarter.

    SPDR S&P Insurance ETF Stock Up 1.1 %

    NYSEARCA:KIE opened at $56.56 on Tuesday. SPDR S&P Insurance ETF has a 52 week low of $41.47 and a 52 week high of $56.76. The company has a fifty day simple moving average of $53.53 and a two-hundred day simple moving average of $51.38. The company has a market cap of $791.84 million, a price-to-earnings ratio of 15.18 and a beta of 0.58.

    About SPDR S&P Insurance ETF

    (Free Report)

    The SPDR S&P Insurance ETF (the Fund), formerly SPDR KBW Insurance ETF, seeks to closely match the returns and characteristics of the S&P Banks Select Industry Index. The Fund invests all, but at least 80%, of its total assets in the securities comprising the Index. The Fund invests in all of the securities represented in the Index in approximately the same proportions as the Index.

    Read More

    Want to see what other hedge funds are holding KIE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for SPDR S&P Insurance ETF (NYSEARCA:KIE – Free Report).

    Institutional Ownership by Quarter for SPDR S&P Insurance ETF (NYSEARCA:KIE)

    Receive News & Ratings for SPDR S&P Insurance ETF Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for SPDR S&P Insurance ETF and related companies with MarketBeat.com’s FREE daily email newsletter.

    [ad_2]

    ABMN Staff

    Source link

  • Equitable Holdings, Inc. (NYSE:EQH) Shares Sold by Daiwa Securities Group Inc.

    Equitable Holdings, Inc. (NYSE:EQH) Shares Sold by Daiwa Securities Group Inc.

    [ad_1]

    Daiwa Securities Group Inc. trimmed its holdings in shares of Equitable Holdings, Inc. (NYSE:EQH – Free Report) by 5.8% during the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 22,693 shares of the company’s stock after selling 1,400 shares during the period. Daiwa Securities Group Inc.’s holdings in Equitable were worth $927,000 at the end of the most recent reporting period.

    Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Vanguard Group Inc. lifted its position in Equitable by 1.2% during the fourth quarter. Vanguard Group Inc. now owns 38,012,452 shares of the company’s stock valued at $1,265,815,000 after buying an additional 446,752 shares in the last quarter. Intech Investment Management LLC grew its position in Equitable by 60.9% in the first quarter. Intech Investment Management LLC now owns 100,476 shares of the company’s stock valued at $3,819,000 after acquiring an additional 38,040 shares in the last quarter. Dynamic Technology Lab Private Ltd acquired a new stake in Equitable in the fourth quarter valued at approximately $362,000. Ashton Thomas Private Wealth LLC grew its position in Equitable by 265.0% in the first quarter. Ashton Thomas Private Wealth LLC now owns 69,503 shares of the company’s stock valued at $2,642,000 after acquiring an additional 50,460 shares in the last quarter. Finally, Teachers Retirement System of The State of Kentucky acquired a new stake in Equitable in the fourth quarter valued at approximately $2,892,000. 92.70% of the stock is owned by institutional investors and hedge funds.

    Wall Street Analysts Forecast Growth

    A number of brokerages have weighed in on EQH. Barclays assumed coverage on Equitable in a research note on Wednesday, September 4th. They set an “overweight” rating and a $59.00 price objective for the company. Citigroup lifted their price objective on Equitable from $41.00 to $53.00 and gave the stock a “buy” rating in a report on Tuesday, July 23rd. Jefferies Financial Group lifted their price objective on Equitable from $46.00 to $51.00 and gave the stock a “buy” rating in a report on Friday, June 28th. UBS Group downgraded Equitable from a “buy” rating to a “neutral” rating and lifted their price objective for the stock from $40.00 to $43.00 in a report on Tuesday, June 18th. Finally, JPMorgan Chase & Co. lifted their price objective on Equitable from $36.00 to $45.00 and gave the stock a “neutral” rating in a report on Tuesday, July 2nd. Four investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. According to data from MarketBeat, Equitable currently has an average rating of “Moderate Buy” and a consensus target price of $46.64.

    Get Our Latest Stock Report on Equitable

    Insider Activity

    In other news, COO Jeffrey J. Hurd sold 9,969 shares of the company’s stock in a transaction on Monday, July 15th. The stock was sold at an average price of $43.09, for a total transaction of $429,564.21. Following the completion of the sale, the chief operating officer now directly owns 111,552 shares of the company’s stock, valued at $4,806,775.68. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. In other news, CEO Mark Pearson sold 30,000 shares of the company’s stock in a transaction on Thursday, August 29th. The stock was sold at an average price of $42.20, for a total transaction of $1,266,000.00. Following the completion of the sale, the chief executive officer now directly owns 678,555 shares of the company’s stock, valued at $28,635,021. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, COO Jeffrey J. Hurd sold 9,969 shares of the company’s stock in a transaction on Monday, July 15th. The shares were sold at an average price of $43.09, for a total value of $429,564.21. Following the transaction, the chief operating officer now directly owns 111,552 shares in the company, valued at $4,806,775.68. The disclosure for this sale can be found here. 1.10% of the stock is currently owned by company insiders.

    Equitable Trading Up 2.1 %

    Shares of EQH stock opened at $40.12 on Monday. The company has a debt-to-equity ratio of 3.06, a quick ratio of 0.12 and a current ratio of 0.12. Equitable Holdings, Inc. has a 1 year low of $24.65 and a 1 year high of $44.50. The stock has a fifty day moving average of $40.88 and a two-hundred day moving average of $39.28. The firm has a market capitalization of $13.05 billion, a PE ratio of 12.42 and a beta of 1.42.

    Equitable (NYSE:EQH – Get Free Report) last announced its quarterly earnings data on Tuesday, July 30th. The company reported $1.43 earnings per share for the quarter, beating the consensus estimate of $1.40 by $0.03. The business had revenue of $3.51 billion during the quarter, compared to analyst estimates of $3.71 billion. Equitable had a return on equity of 87.49% and a net margin of 7.87%. The company’s revenue was up 47.7% on a year-over-year basis. During the same quarter in the prior year, the firm posted $1.17 earnings per share. As a group, research analysts expect that Equitable Holdings, Inc. will post 6.01 EPS for the current year.

    Equitable Dividend Announcement

    The business also recently announced a quarterly dividend, which was paid on Tuesday, August 13th. Stockholders of record on Tuesday, August 6th were issued a dividend of $0.24 per share. This represents a $0.96 annualized dividend and a dividend yield of 2.39%. The ex-dividend date was Tuesday, August 6th. Equitable’s dividend payout ratio is 29.72%.

    Equitable Company Profile

    (Free Report)

    Equitable Holdings, Inc, together with its consolidated subsidiaries, operates as a diversified financial services company worldwide. The company operates through six segments: Individual Retirement, Group Retirement, Investment Management and Research, Protection Solutions, Wealth Management, and Legacy.

    See Also

    Want to see what other hedge funds are holding EQH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Equitable Holdings, Inc. (NYSE:EQH – Free Report).

    Institutional Ownership by Quarter for Equitable (NYSE:EQH)

    Receive News & Ratings for Equitable Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Equitable and related companies with MarketBeat.com’s FREE daily email newsletter.

    [ad_2]

    ABMN Staff

    Source link

  • Johnson & Johnson (NYSE:JNJ) Shares Sold by HBK Sorce Advisory LLC

    Johnson & Johnson (NYSE:JNJ) Shares Sold by HBK Sorce Advisory LLC

    [ad_1]

    HBK Sorce Advisory LLC cut its holdings in shares of Johnson & Johnson (NYSE:JNJ – Free Report) by 4.5% in the second quarter, HoldingsChannel reports. The firm owned 53,703 shares of the company’s stock after selling 2,517 shares during the period. HBK Sorce Advisory LLC’s holdings in Johnson & Johnson were worth $7,849,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

    Several other hedge funds also recently added to or reduced their stakes in the business. Gilbert & Cook Inc. raised its stake in Johnson & Johnson by 3.3% in the 4th quarter. Gilbert & Cook Inc. now owns 9,111 shares of the company’s stock valued at $1,428,000 after purchasing an additional 288 shares during the last quarter. 9258 Wealth Management LLC boosted its position in Johnson & Johnson by 2.1% during the fourth quarter. 9258 Wealth Management LLC now owns 22,034 shares of the company’s stock worth $3,454,000 after acquiring an additional 443 shares during the last quarter. Gryphon Financial Partners LLC raised its holdings in Johnson & Johnson by 66.3% in the 4th quarter. Gryphon Financial Partners LLC now owns 14,245 shares of the company’s stock valued at $2,244,000 after acquiring an additional 5,680 shares during the last quarter. Wade G W & Inc. lifted its stake in Johnson & Johnson by 0.6% in the 4th quarter. Wade G W & Inc. now owns 217,026 shares of the company’s stock worth $34,017,000 after purchasing an additional 1,332 shares in the last quarter. Finally, Inceptionr LLC acquired a new position in shares of Johnson & Johnson during the 4th quarter worth approximately $404,000. 69.55% of the stock is owned by hedge funds and other institutional investors.

    Insider Transactions at Johnson & Johnson

    In related news, VP Robert J. Decker sold 5,635 shares of Johnson & Johnson stock in a transaction that occurred on Friday, August 30th. The shares were sold at an average price of $165.06, for a total value of $930,113.10. Following the completion of the transaction, the vice president now owns 18,973 shares in the company, valued at $3,131,683.38. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Corporate insiders own 0.16% of the company’s stock.

    Analyst Ratings Changes

    A number of equities analysts recently commented on JNJ shares. Sanford C. Bernstein lifted their price objective on Johnson & Johnson from $161.00 to $171.00 in a research report on Thursday, July 18th. The Goldman Sachs Group lowered their price target on shares of Johnson & Johnson from $160.00 to $155.00 and set a “neutral” rating on the stock in a research report on Friday, July 19th. StockNews.com upgraded shares of Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research report on Saturday. Royal Bank of Canada reissued an “outperform” rating and issued a $175.00 price target on shares of Johnson & Johnson in a research note on Tuesday, July 30th. Finally, Cantor Fitzgerald reiterated an “overweight” rating and issued a $215.00 price objective on shares of Johnson & Johnson in a report on Monday, September 9th. Seven equities research analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $173.21.

    Read Our Latest Stock Analysis on JNJ

    Johnson & Johnson Stock Up 0.5 %

    Shares of JNJ opened at $165.52 on Friday. The company has a debt-to-equity ratio of 0.44, a quick ratio of 0.85 and a current ratio of 1.07. The stock has a market capitalization of $398.45 billion, a PE ratio of 10.32, a P/E/G ratio of 2.71 and a beta of 0.53. The company’s 50-day simple moving average is $159.55 and its 200-day simple moving average is $153.99. Johnson & Johnson has a 1 year low of $143.13 and a 1 year high of $168.85.

    Johnson & Johnson (NYSE:JNJ – Get Free Report) last issued its quarterly earnings results on Wednesday, July 17th. The company reported $2.82 EPS for the quarter, beating the consensus estimate of $2.71 by $0.11. Johnson & Johnson had a net margin of 46.34% and a return on equity of 36.60%. The company had revenue of $22.45 billion during the quarter, compared to analysts’ expectations of $22.33 billion. During the same quarter last year, the company posted $2.80 EPS. The firm’s revenue was up 4.3% compared to the same quarter last year. Analysts forecast that Johnson & Johnson will post 10.02 earnings per share for the current fiscal year.

    Johnson & Johnson Announces Dividend

    The business also recently declared a quarterly dividend, which was paid on Tuesday, September 10th. Shareholders of record on Tuesday, August 27th were given a $1.24 dividend. This represents a $4.96 dividend on an annualized basis and a yield of 3.00%. The ex-dividend date of this dividend was Tuesday, August 27th. Johnson & Johnson’s dividend payout ratio is currently 30.92%.

    Johnson & Johnson Company Profile

    (Free Report)

    Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company’s Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.

    Featured Stories

    Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ – Free Report).

    Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

    Receive News & Ratings for Johnson & Johnson Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Johnson & Johnson and related companies with MarketBeat.com’s FREE daily email newsletter.

    [ad_2]

    ABMN Staff

    Source link

  • Bank of New York Mellon Corp Increases Position in Silk Road Medical, Inc (NASDAQ:SILK)

    Bank of New York Mellon Corp Increases Position in Silk Road Medical, Inc (NASDAQ:SILK)

    [ad_1]

    Bank of New York Mellon Corp lifted its stake in Silk Road Medical, Inc (NASDAQ:SILK – Free Report) by 19.8% in the 2nd quarter, Holdings Channel reports. The firm owned 138,529 shares of the company’s stock after purchasing an additional 22,866 shares during the quarter. Bank of New York Mellon Corp’s holdings in Silk Road Medical were worth $3,746,000 at the end of the most recent reporting period.

    A number of other institutional investors have also recently added to or reduced their stakes in SILK. PNC Financial Services Group Inc. lifted its position in shares of Silk Road Medical by 1,293.9% during the 4th quarter. PNC Financial Services Group Inc. now owns 2,523 shares of the company’s stock valued at $31,000 after acquiring an additional 2,342 shares during the period. Quest Partners LLC acquired a new position in Silk Road Medical during the fourth quarter worth $62,000. SG Americas Securities LLC purchased a new stake in Silk Road Medical during the first quarter worth $109,000. State Board of Administration of Florida Retirement System grew its holdings in Silk Road Medical by 9.9% in the first quarter. State Board of Administration of Florida Retirement System now owns 12,065 shares of the company’s stock valued at $221,000 after purchasing an additional 1,090 shares during the last quarter. Finally, Bayesian Capital Management LP acquired a new stake in Silk Road Medical in the first quarter valued at $249,000.

    Insider Buying and Selling

    In other Silk Road Medical news, EVP Kevin M. Klemz sold 2,268 shares of Silk Road Medical stock in a transaction on Monday, August 19th. The shares were sold at an average price of $27.10, for a total value of $61,462.80. Following the transaction, the executive vice president now owns 162,926 shares in the company, valued at approximately $4,415,294.60. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 3.90% of the stock is currently owned by company insiders.

    Analyst Upgrades and Downgrades

    Several research firms have recently issued reports on SILK. Argus downgraded Silk Road Medical from a “buy” rating to a “sell” rating in a research note on Thursday, July 11th. Lake Street Capital restated a “hold” rating and set a $27.50 target price (down previously from $28.00) on shares of Silk Road Medical in a research report on Tuesday, June 18th. Finally, Stifel Nicolaus reiterated a “hold” rating and issued a $27.50 price target (up from $23.00) on shares of Silk Road Medical in a research report on Wednesday, July 17th. Two analysts have rated the stock with a sell rating and seven have issued a hold rating to the company. According to MarketBeat.com, the stock has an average rating of “Hold” and a consensus price target of $20.29.

    Get Our Latest Analysis on SILK

    Silk Road Medical Trading Up 0.8 %

    Shares of Silk Road Medical stock opened at $27.50 on Friday. The firm has a market cap of $1.08 billion, a PE ratio of -20.07 and a beta of 1.53. The company has a quick ratio of 6.69, a current ratio of 7.63 and a debt-to-equity ratio of 0.49. Silk Road Medical, Inc has a fifty-two week low of $6.08 and a fifty-two week high of $27.50. The business’s fifty day moving average is $27.09 and its two-hundred day moving average is $22.71.

    Silk Road Medical (NASDAQ:SILK – Get Free Report) last issued its quarterly earnings results on Wednesday, August 7th. The company reported ($0.42) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.04). Silk Road Medical had a negative return on equity of 37.30% and a negative net margin of 29.53%. The business had revenue of $51.20 million during the quarter, compared to analyst estimates of $49.74 million. During the same period in the previous year, the business posted ($0.35) earnings per share. The firm’s quarterly revenue was up 13.0% on a year-over-year basis. Analysts anticipate that Silk Road Medical, Inc will post -1.45 earnings per share for the current year.

    About Silk Road Medical

    (Free Report)

    Silk Road Medical, Inc operates as a medical device company in the United States. The company offers various products for the treatment of carotid artery disease called transcarotid artery revascularization (TCAR). Its products comprise ENROUTE Transcarotid Neuroprotection System that is used to directly access the common carotid artery and establish temporary blood flow reversal; ENROUTE Transcarotid Stent System for transcarotid access; ENHANCE Transcarotid Peripheral Access Kit, which is used to gain initial access to the common carotid artery; ENROUTE 0.014 Guidewire for atraumatic vessel navigation and target lesion crossing for delivery of interventional devices; and ENROUTE Enflate Transcarotid RX Balloon Dilation Catheter, a transcarotid rapid exchange balloon for the TCAR procedure.

    Featured Stories

    Want to see what other hedge funds are holding SILK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Silk Road Medical, Inc (NASDAQ:SILK – Free Report).

    Institutional Ownership by Quarter for Silk Road Medical (NASDAQ:SILK)

    Receive News & Ratings for Silk Road Medical Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Silk Road Medical and related companies with MarketBeat.com’s FREE daily email newsletter.

    [ad_2]

    ABMN Staff

    Source link

  • Quest Partners LLC Purchases 111 Shares of Adobe Inc. (NASDAQ:ADBE)

    Quest Partners LLC Purchases 111 Shares of Adobe Inc. (NASDAQ:ADBE)

    [ad_1]

    Quest Partners LLC increased its position in shares of Adobe Inc. (NASDAQ:ADBE – Free Report) by 23.3% during the second quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 588 shares of the software company’s stock after acquiring an additional 111 shares during the period. Quest Partners LLC’s holdings in Adobe were worth $327,000 at the end of the most recent reporting period.

    A number of other institutional investors have also recently made changes to their positions in the stock. Trium Capital LLP grew its position in shares of Adobe by 2.9% in the 2nd quarter. Trium Capital LLP now owns 8,612 shares of the software company’s stock valued at $4,784,000 after buying an additional 240 shares during the last quarter. Werba Rubin Papier Wealth Management grew its position in shares of Adobe by 2.0% in the 2nd quarter. Werba Rubin Papier Wealth Management now owns 1,169 shares of the software company’s stock valued at $649,000 after buying an additional 23 shares during the last quarter. Arlington Trust Co LLC grew its position in shares of Adobe by 5.6% in the 2nd quarter. Arlington Trust Co LLC now owns 2,807 shares of the software company’s stock valued at $1,559,000 after buying an additional 150 shares during the last quarter. Koss Olinger Consulting LLC bought a new stake in shares of Adobe in the 2nd quarter valued at about $439,000. Finally, Caprock Group LLC grew its position in shares of Adobe by 53.2% in the 2nd quarter. Caprock Group LLC now owns 17,639 shares of the software company’s stock valued at $9,800,000 after buying an additional 6,129 shares during the last quarter. Institutional investors own 81.79% of the company’s stock.

    Analyst Upgrades and Downgrades

    A number of equities research analysts have commented on ADBE shares. Sanford C. Bernstein reduced their price target on Adobe from $660.00 to $644.00 and set an “outperform” rating on the stock in a research report on Friday. Mizuho reissued a “buy” rating and issued a $640.00 price objective (down from $680.00) on shares of Adobe in a research note on Friday, June 7th. UBS Group dropped their price objective on Adobe from $560.00 to $550.00 and set a “neutral” rating on the stock in a research note on Friday. Oppenheimer reissued an “outperform” rating and issued a $625.00 price objective on shares of Adobe in a research note on Friday. Finally, Melius Research reissued a “hold” rating and issued a $510.00 price objective on shares of Adobe in a research note on Monday, June 10th. Two equities research analysts have rated the stock with a sell rating, seven have issued a hold rating and twenty-one have issued a buy rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $608.83.

    Check Out Our Latest Stock Report on ADBE

    Insider Activity

    In other Adobe news, CAO Mark S. Garfield sold 151 shares of the stock in a transaction on Tuesday, July 16th. The stock was sold at an average price of $564.60, for a total transaction of $85,254.60. Following the completion of the transaction, the chief accounting officer now directly owns 2,797 shares of the company’s stock, valued at $1,579,186.20. The sale was disclosed in a filing with the SEC, which is available through the SEC website. In other Adobe news, CAO Mark S. Garfield sold 264 shares of the stock in a transaction on Monday, June 17th. The stock was sold at an average price of $525.51, for a total transaction of $138,734.64. Following the completion of the transaction, the chief accounting officer now directly owns 2,740 shares of the company’s stock, valued at $1,439,897.40. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, CAO Mark S. Garfield sold 151 shares of the stock in a transaction on Tuesday, July 16th. The shares were sold at an average price of $564.60, for a total value of $85,254.60. Following the transaction, the chief accounting officer now directly owns 2,797 shares of the company’s stock, valued at $1,579,186.20. The disclosure for this sale can be found here. Insiders sold a total of 27,523 shares of company stock valued at $14,994,277 over the last three months. Corporate insiders own 0.15% of the company’s stock.

    Adobe Stock Performance

    ADBE stock opened at $536.87 on Friday. The firm has a market cap of $238.05 billion, a PE ratio of 48.24, a P/E/G ratio of 3.03 and a beta of 1.29. The company has a quick ratio of 1.16, a current ratio of 1.16 and a debt-to-equity ratio of 0.28. The business has a 50 day moving average of $553.76 and a 200-day moving average of $520.19. Adobe Inc. has a 12-month low of $433.97 and a 12-month high of $638.25.

    Adobe (NASDAQ:ADBE – Get Free Report) last released its earnings results on Thursday, September 12th. The software company reported $4.65 earnings per share (EPS) for the quarter, beating the consensus estimate of $4.53 by $0.12. The company had revenue of $5.41 billion during the quarter, compared to analyst estimates of $5.37 billion. Adobe had a return on equity of 40.67% and a net margin of 24.86%. Adobe’s quarterly revenue was up 10.6% on a year-over-year basis. During the same period in the prior year, the company posted $3.26 earnings per share. As a group, sell-side analysts expect that Adobe Inc. will post 14.69 earnings per share for the current year.

    Adobe Profile

    (Free Report)

    Adobe Inc, together with its subsidiaries, operates as a diversified software company worldwide. It operates through three segments: Digital Media, Digital Experience, and Publishing and Advertising. The Digital Media segment offers products, services, and solutions that enable individuals, teams, and enterprises to create, publish, and promote content; and Document Cloud, a unified cloud-based document services platform.

    Further Reading

    Institutional Ownership by Quarter for Adobe (NASDAQ:ADBE)

    Receive News & Ratings for Adobe Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Adobe and related companies with MarketBeat.com’s FREE daily email newsletter.

    [ad_2]

    ABMN Staff

    Source link

  • Bahl & Gaynor Inc. Lowers Position in Elevance Health, Inc. (NYSE:ELV)

    Bahl & Gaynor Inc. Lowers Position in Elevance Health, Inc. (NYSE:ELV)

    [ad_1]

    Bahl & Gaynor Inc. trimmed its stake in shares of Elevance Health, Inc. (NYSE:ELV – Free Report) by 6.5% in the 2nd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 373 shares of the company’s stock after selling 26 shares during the period. Bahl & Gaynor Inc.’s holdings in Elevance Health were worth $202,000 at the end of the most recent quarter.

    Other institutional investors and hedge funds also recently bought and sold shares of the company. Bank & Trust Co purchased a new position in shares of Elevance Health during the second quarter valued at about $27,000. Pin Oak Investment Advisors Inc. purchased a new position in Elevance Health during the 4th quarter valued at approximately $28,000. Palisade Asset Management LLC purchased a new position in Elevance Health during the 1st quarter valued at approximately $28,000. Opal Wealth Advisors LLC bought a new stake in Elevance Health in the 2nd quarter worth approximately $28,000. Finally, Strategic Financial Concepts LLC bought a new position in shares of Elevance Health during the 2nd quarter valued at approximately $30,000. 89.24% of the stock is currently owned by institutional investors.

    Elevance Health Stock Up 0.4 %

    NYSE:ELV opened at $545.78 on Friday. The stock has a fifty day simple moving average of $534.70 and a 200-day simple moving average of $527.40. The company has a current ratio of 1.49, a quick ratio of 1.49 and a debt-to-equity ratio of 0.58. The company has a market cap of $126.85 billion, a price-to-earnings ratio of 20.63, a price-to-earnings-growth ratio of 1.19 and a beta of 0.82. Elevance Health, Inc. has a twelve month low of $431.38 and a twelve month high of $567.26.

    Elevance Health (NYSE:ELV – Get Free Report) last released its quarterly earnings data on Wednesday, July 17th. The company reported $10.12 earnings per share (EPS) for the quarter, beating the consensus estimate of $9.99 by $0.13. The company had revenue of $43.22 billion during the quarter, compared to analysts’ expectations of $42.99 billion. Elevance Health had a net margin of 3.89% and a return on equity of 20.64%. The firm’s quarterly revenue was down .4% on a year-over-year basis. During the same period in the previous year, the company earned $9.04 EPS. Analysts anticipate that Elevance Health, Inc. will post 37.25 EPS for the current year.

    Elevance Health Announces Dividend

    The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, September 25th. Investors of record on Tuesday, September 10th will be paid a $1.63 dividend. The ex-dividend date is Tuesday, September 10th. This represents a $6.52 annualized dividend and a yield of 1.19%. Elevance Health’s dividend payout ratio (DPR) is currently 24.64%.

    Analysts Set New Price Targets

    ELV has been the topic of a number of recent research reports. TD Cowen decreased their price target on shares of Elevance Health from $624.00 to $589.00 and set a “buy” rating on the stock in a research note on Friday, July 19th. Bank of America restated a “neutral” rating and set a $530.00 target price (down from $646.00) on shares of Elevance Health in a research report on Thursday, July 18th. Stephens reiterated an “overweight” rating and issued a $615.00 price target on shares of Elevance Health in a research report on Thursday, September 5th. Truist Financial upped their price objective on Elevance Health from $600.00 to $620.00 and gave the company a “buy” rating in a research report on Monday, July 15th. Finally, Wells Fargo & Company cut their target price on Elevance Health from $600.00 to $593.00 and set an “overweight” rating on the stock in a research report on Monday, July 22nd. One research analyst has rated the stock with a hold rating, fourteen have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Buy” and a consensus price target of $604.29.

    Read Our Latest Report on ELV

    Insiders Place Their Bets

    In other Elevance Health news, Director Robert L. Dixon, Jr. sold 305 shares of the company’s stock in a transaction on Friday, July 19th. The stock was sold at an average price of $506.76, for a total value of $154,561.80. Following the completion of the sale, the director now directly owns 9,721 shares in the company, valued at approximately $4,926,213.96. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. In related news, CEO Gail Boudreaux sold 34,000 shares of the business’s stock in a transaction that occurred on Monday, July 22nd. The shares were sold at an average price of $500.98, for a total value of $17,033,320.00. Following the completion of the transaction, the chief executive officer now owns 126,709 shares of the company’s stock, valued at $63,478,674.82. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Robert L. Dixon, Jr. sold 305 shares of the stock in a transaction on Friday, July 19th. The shares were sold at an average price of $506.76, for a total value of $154,561.80. Following the sale, the director now directly owns 9,721 shares in the company, valued at approximately $4,926,213.96. The disclosure for this sale can be found here. Insiders have sold 35,058 shares of company stock worth $17,588,116 in the last ninety days. 0.35% of the stock is owned by company insiders.

    Elevance Health Profile

    (Free Report)

    Elevance Health, Inc, together with its subsidiaries, operates as a health benefits company in the United States. The company operates through four segments: Health Benefits, CarelonRx, Carelon Services, and Corporate & Other. It offers a variety of health plans and services to program members; health products; an array of fee-based administrative managed care services; and specialty and other insurance products and services, such as stop loss, dental, vision, life, disability, and supplemental health insurance benefits.

    Further Reading

    Want to see what other hedge funds are holding ELV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Elevance Health, Inc. (NYSE:ELV – Free Report).

    Institutional Ownership by Quarter for Elevance Health (NYSE:ELV)

    Receive News & Ratings for Elevance Health Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Elevance Health and related companies with MarketBeat.com’s FREE daily email newsletter.

    [ad_2]

    ABMN Staff

    Source link

  • PFG Investments LLC Sells 1,127 Shares of Dollar General Co. (NYSE:DG)

    PFG Investments LLC Sells 1,127 Shares of Dollar General Co. (NYSE:DG)

    [ad_1]

    PFG Investments LLC cut its position in shares of Dollar General Co. (NYSE:DG – Free Report) by 32.3% in the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 2,365 shares of the company’s stock after selling 1,127 shares during the period. PFG Investments LLC’s holdings in Dollar General were worth $313,000 as of its most recent filing with the Securities & Exchange Commission.

    Several other hedge funds have also made changes to their positions in the company. Dimensional Fund Advisors LP boosted its stake in shares of Dollar General by 4.5% during the fourth quarter. Dimensional Fund Advisors LP now owns 1,211,391 shares of the company’s stock valued at $164,684,000 after purchasing an additional 51,937 shares in the last quarter. Envestnet Portfolio Solutions Inc. increased its holdings in shares of Dollar General by 3.8% in the 4th quarter. Envestnet Portfolio Solutions Inc. now owns 14,996 shares of the company’s stock valued at $2,039,000 after acquiring an additional 551 shares during the period. Avantax Advisory Services Inc. raised its position in shares of Dollar General by 4.4% in the 4th quarter. Avantax Advisory Services Inc. now owns 9,557 shares of the company’s stock worth $1,299,000 after acquiring an additional 407 shares in the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. lifted its stake in shares of Dollar General by 21.4% during the 4th quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 238,485 shares of the company’s stock worth $31,421,000 after purchasing an additional 42,066 shares during the last quarter. Finally, Janney Montgomery Scott LLC boosted its position in Dollar General by 38.7% during the fourth quarter. Janney Montgomery Scott LLC now owns 81,248 shares of the company’s stock valued at $11,046,000 after purchasing an additional 22,656 shares in the last quarter. 91.77% of the stock is currently owned by hedge funds and other institutional investors.

    Insider Activity at Dollar General

    In other news, Director Warren F. Bryant bought 500 shares of Dollar General stock in a transaction on Thursday, September 5th. The stock was acquired at an average price of $80.40 per share, with a total value of $40,200.00. Following the completion of the acquisition, the director now directly owns 41,030 shares of the company’s stock, valued at $3,298,812. The purchase was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. In other Dollar General news, Director Warren F. Bryant bought 500 shares of the company’s stock in a transaction dated Thursday, September 5th. The stock was acquired at an average price of $80.40 per share, with a total value of $40,200.00. Following the completion of the acquisition, the director now directly owns 41,030 shares of the company’s stock, valued at $3,298,812. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Warren F. Bryant purchased 1,000 shares of the firm’s stock in a transaction dated Tuesday, September 10th. The stock was acquired at an average cost of $80.83 per share, for a total transaction of $80,830.00. Following the completion of the purchase, the director now owns 42,030 shares of the company’s stock, valued at approximately $3,397,284.90. The disclosure for this purchase can be found here. 0.49% of the stock is currently owned by corporate insiders.

    Analysts Set New Price Targets

    DG has been the subject of a number of recent research reports. BMO Capital Markets decreased their price target on shares of Dollar General from $130.00 to $90.00 and set a “market perform” rating for the company in a research report on Friday, August 30th. Barclays decreased their target price on shares of Dollar General from $154.00 to $102.00 and set an “overweight” rating for the company in a research report on Tuesday, September 3rd. Gordon Haskett lowered shares of Dollar General from a “buy” rating to a “hold” rating and set a $90.00 price target on the stock. in a report on Friday, August 30th. Wells Fargo & Company reduced their price target on Dollar General from $145.00 to $130.00 and set an “equal weight” rating on the stock in a research report on Tuesday, August 27th. Finally, Oppenheimer reissued a “market perform” rating on shares of Dollar General in a research report on Monday, August 26th. One research analyst has rated the stock with a sell rating, sixteen have assigned a hold rating and six have given a buy rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus target price of $113.95.

    Check Out Our Latest Report on DG

    Dollar General Stock Performance

    Shares of DG stock opened at $83.21 on Friday. The company has a quick ratio of 0.24, a current ratio of 1.22 and a debt-to-equity ratio of 0.86. Dollar General Co. has a 52-week low of $77.96 and a 52-week high of $168.07. The business has a 50-day simple moving average of $113.67 and a 200-day simple moving average of $132.50. The stock has a market cap of $18.30 billion, a PE ratio of 12.11, a price-to-earnings-growth ratio of 2.41 and a beta of 0.45.

    Dollar General (NYSE:DG – Get Free Report) last posted its quarterly earnings data on Thursday, August 29th. The company reported $1.70 EPS for the quarter, missing analysts’ consensus estimates of $1.79 by ($0.09). Dollar General had a net margin of 3.57% and a return on equity of 20.62%. The business had revenue of $10.21 billion during the quarter, compared to analysts’ expectations of $10.37 billion. During the same quarter last year, the firm earned $2.13 earnings per share. The firm’s quarterly revenue was up 4.2% compared to the same quarter last year. On average, equities analysts expect that Dollar General Co. will post 5.86 EPS for the current year.

    Dollar General Announces Dividend

    The business also recently declared a quarterly dividend, which will be paid on Tuesday, October 22nd. Investors of record on Tuesday, October 8th will be given a dividend of $0.59 per share. The ex-dividend date is Tuesday, October 8th. This represents a $2.36 annualized dividend and a dividend yield of 2.84%. Dollar General’s dividend payout ratio (DPR) is presently 34.35%.

    About Dollar General

    (Free Report)

    Dollar General Corporation, a discount retailer, provides various merchandise products in the southern, southwestern, midwestern, and eastern United States. It offers consumable products, including paper and cleaning products, such as paper towels, bath tissues, paper dinnerware, trash and storage bags, disinfectants, and laundry products; packaged food comprising cereals, pasta, canned soups, fruits and vegetables, condiments, spices, sugar, and flour; and perishables that include milk, eggs, bread, refrigerated and frozen food, beer, and wine.

    Featured Articles

    Want to see what other hedge funds are holding DG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Dollar General Co. (NYSE:DG – Free Report).

    Institutional Ownership by Quarter for Dollar General (NYSE:DG)

    Receive News & Ratings for Dollar General Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Dollar General and related companies with MarketBeat.com’s FREE daily email newsletter.

    [ad_2]

    ABMN Staff

    Source link

  • Lantz Financial LLC Sells 2,186 Shares of AT&T Inc. (NYSE:T)

    Lantz Financial LLC Sells 2,186 Shares of AT&T Inc. (NYSE:T)

    [ad_1]

    Lantz Financial LLC trimmed its stake in AT&T Inc. (NYSE:T – Free Report) by 10.1% in the second quarter, Holdings Channel reports. The firm owned 19,510 shares of the technology company’s stock after selling 2,186 shares during the quarter. Lantz Financial LLC’s holdings in AT&T were worth $373,000 as of its most recent SEC filing.

    Several other large investors also recently made changes to their positions in the stock. Cantor Fitzgerald Investment Advisors L.P. bought a new position in AT&T during the 4th quarter worth $11,554,000. Clearbridge Investments LLC increased its stake in AT&T by 250.3% during the 4th quarter. Clearbridge Investments LLC now owns 67,303 shares of the technology company’s stock worth $1,129,000 after acquiring an additional 48,091 shares during the period. Skopos Labs Inc. acquired a new position in AT&T in the 4th quarter valued at $839,000. M&G Plc bought a new stake in shares of AT&T during the 1st quarter valued at $9,074,000. Finally, Foundations Investment Advisors LLC grew its holdings in shares of AT&T by 115.8% during the 4th quarter. Foundations Investment Advisors LLC now owns 196,236 shares of the technology company’s stock worth $3,540,000 after purchasing an additional 105,284 shares in the last quarter. Institutional investors and hedge funds own 57.10% of the company’s stock.

    AT&T Stock Up 1.0 %

    AT&T stock opened at $21.71 on Wednesday. The firm has a market cap of $155.66 billion, a price-to-earnings ratio of 11.67, a PEG ratio of 3.57 and a beta of 0.59. AT&T Inc. has a 52-week low of $14.12 and a 52-week high of $21.86. The company has a debt-to-equity ratio of 1.05, a quick ratio of 0.66 and a current ratio of 0.70. The firm has a 50 day moving average price of $19.42 and a two-hundred day moving average price of $18.09.

    AT&T (NYSE:T – Get Free Report) last issued its quarterly earnings results on Wednesday, July 24th. The technology company reported $0.57 earnings per share for the quarter, hitting analysts’ consensus estimates of $0.57. The firm had revenue of $29.80 billion during the quarter, compared to the consensus estimate of $30.05 billion. AT&T had a return on equity of 14.16% and a net margin of 10.41%. The business’s revenue was down .3% compared to the same quarter last year. During the same period last year, the business posted $0.63 EPS. Equities analysts predict that AT&T Inc. will post 2.2 EPS for the current year.

    AT&T Announces Dividend

    The business also recently announced a quarterly dividend, which was paid on Thursday, August 1st. Investors of record on Wednesday, July 10th were paid a dividend of $0.2775 per share. This represents a $1.11 annualized dividend and a yield of 5.11%. The ex-dividend date was Wednesday, July 10th. AT&T’s dividend payout ratio is presently 59.68%.

    Analysts Set New Price Targets

    T has been the subject of several analyst reports. Daiwa America upgraded shares of AT&T to a “hold” rating in a research report on Friday, July 26th. The Goldman Sachs Group started coverage on AT&T in a report on Monday, July 1st. They issued a “buy” rating and a $22.00 target price on the stock. TD Cowen boosted their price target on AT&T from $21.00 to $23.00 and gave the stock a “hold” rating in a report on Thursday, July 25th. Moffett Nathanson raised their price objective on AT&T from $17.00 to $18.00 and gave the company a “neutral” rating in a research note on Thursday, August 15th. Finally, Evercore ISI boosted their target price on AT&T from $18.00 to $19.00 and gave the stock an “in-line” rating in a research note on Thursday, July 25th. Nine analysts have rated the stock with a hold rating and ten have given a buy rating to the company’s stock. Based on data from MarketBeat.com, AT&T currently has an average rating of “Moderate Buy” and a consensus target price of $22.06.

    Get Our Latest Stock Analysis on AT&T

    AT&T Company Profile

    (Free Report)

    AT&T Inc provides telecommunications and technology services worldwide. The company operates through two segments, Communications and Latin America. The Communications segment offers wireless voice and data communications services; and sells handsets, wireless data cards, wireless computing devices, carrying cases/protective covers, and wireless chargers through its own company-owned stores, agents, and third-party retail stores.

    Featured Stories

    Want to see what other hedge funds are holding T? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AT&T Inc. (NYSE:T – Free Report).

    Institutional Ownership by Quarter for AT&T (NYSE:T)

    Receive News & Ratings for AT&T Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for AT&T and related companies with MarketBeat.com’s FREE daily email newsletter.

    [ad_2]

    ABMN Staff

    Source link

  • Prestige Wealth Management Group LLC Sells 30 Shares of Invesco QQQ (NASDAQ:QQQ)

    Prestige Wealth Management Group LLC Sells 30 Shares of Invesco QQQ (NASDAQ:QQQ)

    [ad_1]

    Prestige Wealth Management Group LLC reduced its stake in shares of Invesco QQQ (NASDAQ:QQQ – Free Report) by 11.1% in the second quarter, according to its most recent filing with the SEC. The institutional investor owned 241 shares of the exchange traded fund’s stock after selling 30 shares during the period. Prestige Wealth Management Group LLC’s holdings in Invesco QQQ were worth $116,000 as of its most recent filing with the SEC.

    Several other institutional investors and hedge funds have also recently modified their holdings of QQQ. Ballentine Partners LLC boosted its holdings in Invesco QQQ by 0.3% during the second quarter. Ballentine Partners LLC now owns 39,092 shares of the exchange traded fund’s stock worth $18,730,000 after purchasing an additional 115 shares during the last quarter. Ellis Investment Partners LLC boosted its stake in shares of Invesco QQQ by 0.9% in the 2nd quarter. Ellis Investment Partners LLC now owns 43,165 shares of the exchange traded fund’s stock worth $20,681,000 after buying an additional 405 shares during the last quarter. Valence8 US LP grew its holdings in shares of Invesco QQQ by 14.9% in the second quarter. Valence8 US LP now owns 76,711 shares of the exchange traded fund’s stock valued at $36,753,000 after acquiring an additional 9,951 shares in the last quarter. Arlington Trust Co LLC grew its holdings in shares of Invesco QQQ by 3.4% in the second quarter. Arlington Trust Co LLC now owns 1,636 shares of the exchange traded fund’s stock valued at $784,000 after acquiring an additional 54 shares in the last quarter. Finally, Koss Olinger Consulting LLC purchased a new stake in shares of Invesco QQQ during the second quarter valued at approximately $2,447,000. 44.58% of the stock is owned by hedge funds and other institutional investors.

    Invesco QQQ Price Performance

    QQQ stock opened at $448.69 on Monday. The stock’s fifty day simple moving average is $472.43 and its two-hundred day simple moving average is $456.33. Invesco QQQ has a 1-year low of $342.35 and a 1-year high of $503.52.

    Invesco QQQ Increases Dividend

    The business also recently declared a quarterly dividend, which was paid on Wednesday, July 31st. Investors of record on Monday, June 24th were given a dividend of $0.7615 per share. The ex-dividend date was Monday, June 24th. This represents a $3.05 annualized dividend and a yield of 0.68%. This is a positive change from Invesco QQQ’s previous quarterly dividend of $0.57.

    About Invesco QQQ

    (Free Report)

    PowerShares QQQ Trust, Series 1 is a unit investment trust that issues securities called Nasdaq-100 Index Tracking Stock. The Trust’s investment objective is to provide investment results that generally correspond to the price and yield performance of the Nasdaq-100 Index. The Trust provides investors with the opportunity to purchase units of beneficial interest in the Trust representing proportionate undivided interests in the portfolio of securities held by the Trust, which consists of substantially all of the securities, in substantially the same weighting, as the component securities of the Nasdaq-100 Index.

    Featured Stories

    Institutional Ownership by Quarter for Invesco QQQ (NASDAQ:QQQ)

    Receive News & Ratings for Invesco QQQ Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Invesco QQQ and related companies with MarketBeat.com’s FREE daily email newsletter.

    [ad_2]

    ABMN Staff

    Source link

  • AT&T Inc. (NYSE:T) Shares Sold by Private Advisor Group LLC

    AT&T Inc. (NYSE:T) Shares Sold by Private Advisor Group LLC

    [ad_1]

    Private Advisor Group LLC cut its holdings in AT&T Inc. (NYSE:T – Free Report) by 1.1% during the 2nd quarter, Holdings Channel reports. The firm owned 684,778 shares of the technology company’s stock after selling 7,383 shares during the period. Private Advisor Group LLC’s holdings in AT&T were worth $13,086,000 at the end of the most recent reporting period.

    Other large investors have also modified their holdings of the company. Vanguard Group Inc. lifted its stake in shares of AT&T by 0.4% during the first quarter. Vanguard Group Inc. now owns 624,994,998 shares of the technology company’s stock valued at $10,999,912,000 after buying an additional 2,588,539 shares during the period. Bank of New York Mellon Corp raised its stake in AT&T by 7.4% during the second quarter. Bank of New York Mellon Corp now owns 81,076,641 shares of the technology company’s stock worth $1,549,375,000 after purchasing an additional 5,592,123 shares during the period. Norges Bank purchased a new position in AT&T during the fourth quarter worth approximately $1,118,288,000. Dimensional Fund Advisors LP raised its stake in AT&T by 2.5% during the fourth quarter. Dimensional Fund Advisors LP now owns 47,377,267 shares of the technology company’s stock worth $794,978,000 after purchasing an additional 1,137,792 shares during the period. Finally, LSV Asset Management raised its stake in AT&T by 1.1% during the first quarter. LSV Asset Management now owns 29,777,030 shares of the technology company’s stock worth $524,076,000 after purchasing an additional 333,787 shares during the period. 57.10% of the stock is currently owned by institutional investors and hedge funds.

    AT&T Stock Performance

    AT&T stock opened at $20.97 on Friday. The company has a current ratio of 0.70, a quick ratio of 0.66 and a debt-to-equity ratio of 1.05. AT&T Inc. has a 1 year low of $14.12 and a 1 year high of $21.00. The company has a market cap of $150.36 billion, a PE ratio of 11.27, a PEG ratio of 3.47 and a beta of 0.59. The company’s 50-day moving average is $19.31 and its two-hundred day moving average is $18.01.

    AT&T (NYSE:T – Get Free Report) last released its quarterly earnings data on Wednesday, July 24th. The technology company reported $0.57 earnings per share for the quarter, hitting the consensus estimate of $0.57. AT&T had a net margin of 10.41% and a return on equity of 14.16%. The business had revenue of $29.80 billion for the quarter, compared to analyst estimates of $30.05 billion. During the same quarter last year, the firm earned $0.63 EPS. AT&T’s quarterly revenue was down .3% compared to the same quarter last year. Equities analysts anticipate that AT&T Inc. will post 2.22 earnings per share for the current year.

    AT&T Dividend Announcement

    The business also recently announced a quarterly dividend, which was paid on Thursday, August 1st. Shareholders of record on Wednesday, July 10th were issued a dividend of $0.2775 per share. The ex-dividend date was Wednesday, July 10th. This represents a $1.11 annualized dividend and a yield of 5.29%. AT&T’s dividend payout ratio (DPR) is currently 59.68%.

    Analyst Upgrades and Downgrades

    A number of brokerages have recently commented on T. Royal Bank of Canada raised their target price on shares of AT&T from $18.00 to $19.00 and gave the company a “sector perform” rating in a research note on Thursday, July 25th. Barclays raised their price objective on shares of AT&T from $20.00 to $22.00 and gave the stock an “overweight” rating in a report on Thursday, July 25th. UBS Group reaffirmed a “buy” rating and issued a $24.00 price target on shares of AT&T in a report on Tuesday, June 18th. JPMorgan Chase & Co. lifted their price target on shares of AT&T from $21.00 to $24.00 and gave the company an “overweight” rating in a report on Thursday, July 25th. Finally, Evercore ISI lifted their price objective on shares of AT&T from $18.00 to $19.00 and gave the company an “in-line” rating in a research report on Thursday, July 25th. Nine equities research analysts have rated the stock with a hold rating and ten have issued a buy rating to the stock. According to data from MarketBeat.com, AT&T currently has a consensus rating of “Moderate Buy” and an average target price of $22.06.

    Get Our Latest Analysis on AT&T

    AT&T Company Profile

    (Free Report)

    AT&T Inc provides telecommunications and technology services worldwide. The company operates through two segments, Communications and Latin America. The Communications segment offers wireless voice and data communications services; and sells handsets, wireless data cards, wireless computing devices, carrying cases/protective covers, and wireless chargers through its own company-owned stores, agents, and third-party retail stores.

    Read More

    Want to see what other hedge funds are holding T? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AT&T Inc. (NYSE:T – Free Report).

    Institutional Ownership by Quarter for AT&T (NYSE:T)

    Receive News & Ratings for AT&T Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for AT&T and related companies with MarketBeat.com’s FREE daily email newsletter.

    [ad_2]

    ABMN Staff

    Source link

  • Parkside Financial Bank & Trust Cuts Stock Position in Taiwan Semiconductor Manufacturing Company Limited (NYSE:TSM)

    Parkside Financial Bank & Trust Cuts Stock Position in Taiwan Semiconductor Manufacturing Company Limited (NYSE:TSM)

    [ad_1]

    Parkside Financial Bank & Trust lessened its holdings in Taiwan Semiconductor Manufacturing Company Limited (NYSE:TSM – Free Report) by 12.5% in the second quarter, according to its most recent filing with the SEC. The institutional investor owned 1,675 shares of the semiconductor company’s stock after selling 239 shares during the period. Parkside Financial Bank & Trust’s holdings in Taiwan Semiconductor Manufacturing were worth $291,000 as of its most recent SEC filing.

    A number of other institutional investors have also bought and sold shares of the business. Atlantic Edge Private Wealth Management LLC bought a new position in shares of Taiwan Semiconductor Manufacturing during the 2nd quarter valued at about $25,000. Olistico Wealth LLC bought a new position in shares of Taiwan Semiconductor Manufacturing during the 2nd quarter valued at about $27,000. NewSquare Capital LLC bought a new position in shares of Taiwan Semiconductor Manufacturing during the 2nd quarter valued at about $29,000. First Community Trust NA bought a new position in shares of Taiwan Semiconductor Manufacturing during the 2nd quarter valued at about $33,000. Finally, LifeSteps Financial Inc. bought a new position in shares of Taiwan Semiconductor Manufacturing during the 1st quarter valued at about $27,000. Hedge funds and other institutional investors own 16.51% of the company’s stock.

    Taiwan Semiconductor Manufacturing Stock Down 4.2 %

    Shares of NYSE:TSM opened at $156.85 on Friday. The company has a current ratio of 2.47, a quick ratio of 2.21 and a debt-to-equity ratio of 0.26. Taiwan Semiconductor Manufacturing Company Limited has a 12 month low of $84.01 and a 12 month high of $193.47. The company has a market cap of $813.49 billion, a price-to-earnings ratio of 29.88, a PEG ratio of 0.94 and a beta of 1.14. The company has a 50-day moving average price of $169.79 and a 200 day moving average price of $155.09.

    Taiwan Semiconductor Manufacturing (NYSE:TSM – Get Free Report) last posted its quarterly earnings data on Thursday, July 18th. The semiconductor company reported $1.48 earnings per share for the quarter, topping analysts’ consensus estimates of $1.37 by $0.11. Taiwan Semiconductor Manufacturing had a net margin of 37.85% and a return on equity of 25.54%. The company had revenue of $20.82 billion for the quarter, compared to analyst estimates of $20.33 billion. During the same period in the prior year, the company posted $1.14 EPS. The firm’s revenue for the quarter was up 34.6% on a year-over-year basis. As a group, equities research analysts predict that Taiwan Semiconductor Manufacturing Company Limited will post 6.45 earnings per share for the current year.

    Taiwan Semiconductor Manufacturing Increases Dividend

    The company also recently disclosed a quarterly dividend, which will be paid on Thursday, January 9th. Investors of record on Thursday, December 12th will be given a $0.4871 dividend. This is a positive change from Taiwan Semiconductor Manufacturing’s previous quarterly dividend of $0.49. This represents a $1.95 dividend on an annualized basis and a yield of 1.24%. The ex-dividend date is Thursday, December 12th. Taiwan Semiconductor Manufacturing’s dividend payout ratio is 32.57%.

    Analysts Set New Price Targets

    Several research analysts have commented on the stock. TD Cowen increased their price objective on shares of Taiwan Semiconductor Manufacturing from $130.00 to $170.00 and gave the company a “hold” rating in a report on Thursday, July 18th. Susquehanna reissued a “positive” rating and set a $250.00 price objective on shares of Taiwan Semiconductor Manufacturing in a report on Wednesday, August 14th. Needham & Company LLC increased their price target on shares of Taiwan Semiconductor Manufacturing from $168.00 to $210.00 and gave the company a “buy” rating in a report on Monday, July 15th. Barclays increased their price target on shares of Taiwan Semiconductor Manufacturing from $150.00 to $170.00 and gave the company an “overweight” rating in a report on Wednesday, June 5th. Finally, Sanford C. Bernstein increased their price target on shares of Taiwan Semiconductor Manufacturing from $150.00 to $200.00 and gave the company an “outperform” rating in a report on Thursday, June 20th. One equities research analyst has rated the stock with a hold rating and five have given a buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $200.00.

    Get Our Latest Stock Report on TSM

    About Taiwan Semiconductor Manufacturing

    (Free Report)

    Taiwan Semiconductor Manufacturing Company Limited, together with its subsidiaries, manufactures, packages, tests, and sells integrated circuits and other semiconductor devices in Taiwan, China, Europe, the Middle East, Africa, Japan, the United States, and internationally. It provides a range of wafer fabrication processes, including processes to manufacture complementary metal- oxide-semiconductor (CMOS) logic, mixed-signal, radio frequency, embedded memory, bipolar CMOS mixed-signal, and others.

    Featured Stories

    Want to see what other hedge funds are holding TSM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Taiwan Semiconductor Manufacturing Company Limited (NYSE:TSM – Free Report).

    Institutional Ownership by Quarter for Taiwan Semiconductor Manufacturing (NYSE:TSM)

    Receive News & Ratings for Taiwan Semiconductor Manufacturing Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Taiwan Semiconductor Manufacturing and related companies with MarketBeat.com’s FREE daily email newsletter.

    [ad_2]

    ABMN Staff

    Source link

  • FineMark National Bank & Trust Cuts Stake in iShares Russell 2000 Value ETF (NYSEARCA:IWN)

    FineMark National Bank & Trust Cuts Stake in iShares Russell 2000 Value ETF (NYSEARCA:IWN)

    [ad_1]

    FineMark National Bank & Trust lowered its stake in shares of iShares Russell 2000 Value ETF (NYSEARCA:IWN – Free Report) by 19.0% in the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 5,391 shares of the company’s stock after selling 1,262 shares during the period. FineMark National Bank & Trust’s holdings in iShares Russell 2000 Value ETF were worth $821,000 as of its most recent filing with the Securities & Exchange Commission.

    A number of other institutional investors and hedge funds have also modified their holdings of the stock. Pathstone Holdings LLC acquired a new position in iShares Russell 2000 Value ETF during the fourth quarter worth about $37,966,000. Pacific Life Fund Advisors LLC acquired a new position in iShares Russell 2000 Value ETF during the fourth quarter worth about $35,930,000. Picton Mahoney Asset Management boosted its position in iShares Russell 2000 Value ETF by 103.1% during the first quarter. Picton Mahoney Asset Management now owns 325,175 shares of the company’s stock worth $51,642,000 after acquiring an additional 165,046 shares during the last quarter. Quadrature Capital Ltd acquired a new position in iShares Russell 2000 Value ETF during the first quarter worth about $26,071,000. Finally, Cetera Investment Advisers boosted its position in iShares Russell 2000 Value ETF by 211.6% during the first quarter. Cetera Investment Advisers now owns 223,660 shares of the company’s stock worth $35,519,000 after acquiring an additional 151,873 shares during the last quarter.

    iShares Russell 2000 Value ETF Trading Down 0.5 %

    IWN opened at $161.88 on Friday. The firm has a market capitalization of $12.38 billion, a PE ratio of 10.79 and a beta of 1.17. iShares Russell 2000 Value ETF has a twelve month low of $124.97 and a twelve month high of $174.83. The firm’s 50-day moving average price is $161.41 and its 200 day moving average price is $155.98.

    iShares Russell 2000 Value ETF Company Profile

    (Free Report)

    iShares Russell 2000 Value ETF, formerly Ishares Trust Russel 2000 (the Fund), formerly iShares Russell 2000 Value Index Fund, is an exchange traded fund. The Fund seeks investment results that correspond generally to the price and yield performance of the Russell 2000 Value Index (the Index). The Index measures the performance of equity securities of Russell 2000 Index issuers with relatively lower price-to-book ratios and lower forecasted growth.

    See Also

    Want to see what other hedge funds are holding IWN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for iShares Russell 2000 Value ETF (NYSEARCA:IWN – Free Report).

    Institutional Ownership by Quarter for iShares Russell 2000 Value ETF (NYSEARCA:IWN)

    Receive News & Ratings for iShares Russell 2000 Value ETF Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for iShares Russell 2000 Value ETF and related companies with MarketBeat.com’s FREE daily email newsletter.

    [ad_2]

    ABMN Staff

    Source link